AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...

MRI of inhaled perfluoropropane can assess regional lung ventilation and monitor improvements in response to medication ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...